Can a 50-year-old male receiving avelumab (avelumab) for cancer treatment undergo dental implant placement?

Dental Implants in Patients on Avelumab

A 50-year-old male receiving avelumab should generally NOT undergo elective dental implant placement during active cancer therapy, as avelumab is not a bone-modifying agent (BMA) and does not carry the same MRONJ risk as bisphosphonates or denosumab—however, the decision requires careful coordination between oncology and dental specialists to assess individual cancer prognosis, treatment goals, and oral health status.

Key Clinical Distinction

Avelumab is a PD-L1 immune checkpoint inhibitor, NOT a bone-modifying agent 1. The primary concern with dental implants in cancer patients relates to:

• Bone-modifying agents (BMAs): Bisphosphonates and denosumab at oncologic doses
• Anti-angiogenic agents: VEGF inhibitors and similar drugs
• Immune checkpoint inhibitors (ICIs): Different risk profile than BMAs

Evidence-Based Recommendations

For Patients on BMAs (Not Applicable Here)

The 2019 MASCC/ISOO/ASCO guidelines clearly state: "Elective dentoalveolar surgical procedures (e.g., non-medically necessary extractions, alveoloplasties, and implants) should not be performed during active therapy with a BMA at an oncologic dose" 2. However, this applies specifically to bisphosphonates and denosumab, not to avelumab.

For Patients on Avelumab Specifically

Critical distinction: Avelumab does not appear in the MRONJ risk medications list. The guidelines focus on BMAs (zoledronic acid, pamidronate, denosumab) and angiogenic inhibitors as primary MRONJ risk factors 2.

Recent evidence suggests:

• A 2024 systematic review found that anti-angiogenic therapies were more frequently associated with adverse implant outcomes including MRONJ, while immune checkpoint inhibitors showed unclear effects due to sparse data 3
• One case report documented oral manifestations with avelumab but did not specifically address implant complications 4
• Studies demonstrate feasibility of implant placement in cancer patients on various therapies when proper protocols are followed 5

Clinical Decision Algorithm

Step 1: Assess Cancer Prognosis and Treatment Status

• Life expectancy: Is the patient's cancer controlled? What is projected survival?
• Treatment duration: How long will avelumab therapy continue?
• Urgency: Is this medically necessary or purely elective?

Step 2: Evaluate Oral Health Status

Before any consideration:

• Comprehensive dental and periodontal examination
• Full radiographic assessment (panoramic ± periapical films)
• Address active periodontal disease, caries, or infection
• Assess modifiable risk factors: diabetes control, smoking status 2

Step 3: Multidisciplinary Coordination

Required consultation between:

• Oncologist (cancer status, treatment plan, prognosis)
• Dental specialist with MRONJ expertise
• Patient (informed consent regarding risks/benefits)

This coordination is mandatory per guidelines 2.

Step 4: Risk-Benefit Analysis

Proceed with implants if:

• Cancer is controlled/in remission
• Life expectancy supports long-term implant benefit
• Excellent oral hygiene and no active periodontal disease
• Patient understands risks and commits to rigorous follow-up
• Dental specialist experienced in oncology patients is available

Defer implants if:

• Active progressive cancer
• Poor prognosis (<2 years expected survival)
• Uncontrolled diabetes or active smoking
• Poor oral hygiene or active periodontal disease
• Patient cannot commit to intensive monitoring

Special Considerations for Avelumab

Immune-Related Adverse Events

Avelumab can cause immune-related toxicities affecting multiple organ systems 6. While oral complications are rare, the altered immune response could theoretically affect:

• Wound healing
• Infection risk
• Inflammatory responses around implants

Infusion Reactions

Avelumab has the highest rate of infusion reactions among PD-L1 inhibitors (25% any-grade), though severe reactions are rare (0.7%) 6. This is managed with premedication but doesn't directly impact implant decisions.

Practical Management Protocol

If proceeding with implants:

1. Timing: Consider placing implants during treatment breaks if feasible, though evidence doesn't mandate this for ICIs

2. Surgical protocol:

   • Minimize surgical trauma
   • Ensure primary closure
   • Consider submerged healing protocol (as used successfully in BMA patients) 5

3. Follow-up schedule:

   • Evaluate every 6-8 weeks until complete mucosal coverage 2
   • Maintain communication with oncology team
   • Long-term dental follow-up every 6 months 2

4. Patient education:

   • Rigorous oral hygiene (MASCC/ISOO daily oral care plan) 2
   • Immediate reporting of pain, swelling, or exposed bone
   • Lifelong commitment to dental maintenance

Common Pitfalls to Avoid

• Assuming all cancer therapies carry equal MRONJ risk: Avelumab is NOT a BMA and doesn't have the same bone metabolism effects
• Proceeding without oncology consultation: Always coordinate care
• Ignoring patient prognosis: Implants require months to integrate and years to justify the investment
• Inadequate follow-up: Cancer patients need more intensive monitoring than standard implant patients
• Poor patient selection: Active periodontal disease or poor oral hygiene predicts failure

Bottom Line

While avelumab itself is not contraindicated for dental implants (unlike BMAs), the decision must prioritize the patient's cancer prognosis, overall health status, and ability to maintain rigorous oral hygiene. The procedure should only proceed after thorough multidisciplinary discussion and with a dental specialist experienced in managing oncology patients. If the patient has good cancer control, excellent oral health, and realistic expectations, implants can be considered with appropriate informed consent and intensive monitoring protocols 2, 5, 3.